A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2018
At a glance
- Drugs ATI 502 (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
- Sponsors Aclaris Therapeutics
- 03 Aug 2018 According to an Aclaris Therapeutics media release, data from this trial is expected in the first half of 2019.
- 17 May 2018 Planned End Date changed from 18 May 2018 to 18 Jan 2019.
- 17 May 2018 Planned primary completion date changed from 18 May 2018 to 18 Jan 2019.